Dosage & Administration Efficacy safety testing Drug label Prior authorization Financial assistance

Tecentriq

(atezolizumab)

14 ML atezolizumab 60 MG/ML Injection [Tecentriq]20 ML atezolizumab 60 MG/ML Injection [Tecentriq]

NO BLACK BOX WARNING

Dosage & administration

Administer TECENTRIQ intravenously over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.

Urothelial Carcinoma

* Administer TECENTRIQ as a single agent as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks.

NSCLC

* In the adjuvant setting, administer TECENTRIQ following resection and up to 4 cycles of platinum-based chemotherapy as 840 mg every 2 weeks, 1200 mg every 3 weeks or 1680 mg every 4 weeks for up to 1 year.
* In the metastatic setting, administer TECENTRIQ as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks.
* When administering with chemotherapy with or without bevacizumab, administer TECENTRIQ prior to chemotherapy and bevacizumab when given on the same day.

Small Cell Lung Cancer

* Administer TECENTRIQ as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks. When administering with carboplatin and etoposide, administer TECENTRIQ prior to chemotherapy when given on the same day.

Hepatocellular Carcinoma

* Administer TECENTRIQ as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks. Administer TECENTRIQ prior to bevacizumab when given on the same day. Bevacizumab is administered at 15 mg/kg every 3 weeks.

Melanoma

* Following completion of a 28 day cycle of cobimetinib and vemurafenib, administer TECENTRIQ 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks with cobimetinib 60 mg orally once daily (21 days on /7 days off) and vemurafenib 720 mg orally twice daily.

eficacy, safety & testing

Tecentriq clinical details

Biomarker Testing: NSCLC

Mechanism of Action (MOA): Adjuvant NSCLC

Efficacy: Adjuvant NSCLC [IMpower010]

Clinical Trials: Adjuvant NSCLC [IMpower010]

Tecentriq Side Effects: Adjuvant NSCLC

Safety Profile: Adjuvant NSCLC [IMpower010]

Managing Select Adverse Reactions: Adjuvant NSCLC

Dosing and Administration: Adjuvant NSCLC

Dose Modifications: Adjuvant NSCLC

Mechanism of Action (MOA): mNSCLC

Efficacy: mNSCLC - 1L Combination [IMpower150]

Clinical Trial: mNSCLC - 1L Combination [IMpower150]

Safety Profile: mNSCLC - 1L Combination [IMpower150]

Efficacy: mNSCLC - 1L Monotherapy [IMpower110]

Clinical Trial: mNSCLC - 1L Monotherapy [IMpower110]

Safety Profile: mNSCLC - 1L Monotherapy [IMpower110]

Efficacy: mNSCLC - 2L Monotherapy [OAK]

Clinical Trial: mNSCLC - 2L Monotherapy [OAK]

Safety Profile: mNSCLC - 2L Monotherapy [OAK]

Tecentriq Side Effects: mNSCLC

Managing Select Adverse Reactions: mNSCLC

Dosing & Administration: mNSCLC

Dose Modifications: mNSCLC

Mechanism of Action (MOA): SCLC

Efficacy: SCLC [IMpower133]

Clinical Trial: SCLC [IMpower133]

Safety Profile: SCLC [IMpower133]

Tecentriq Side Effects: SCLC

Managing Select Adverse Reactions: SCLC

Dosing and Administration: SCLC

Dose Modifications: SCLC

Mechanism of Action (MOA): HCC

Efficacy (Coprimary Endpoints): HCC [IMbrave150]

Efficacy (Key Secondary Endpoints): HCC [IMbrave150]

Clinical Trial: HCC [IMbrave150]

Patient Reported Outcomes: HCC [IMbrave150]

Tecentriq Side Effects: HCC

Managing Select Adverse Reactions: HCC

Safety Profile: HCC [IMbrave150]

Dosing and Administration: HCC

Dose Modifications: HCC

Mechanism of Action (MOA): Melanoma

Efficacy: Melanoma [IMspire150]

Clinical Trial: Melanoma [IMspire150]

Tecentriq Side Effects: Melanoma

Managing Select Adverse Reactions: Melanoma

Dosing and Administration: Melanoma

Safety Profile: Melanoma [IMspire150]

Dose Modifications: Melanoma

drug label

Tecentriq prescribing information

Have more Tecentriq questions?

Submit MSL Request

Learn More

Need to report a Tecentriq issue?

ONLINE FORMReport adverse event

Learn More

prior authorization

Tecentriq Prior authorization resources

Complete Letter of Medical Necessity

NOT PROVIDED BY BRANDCoverage Authorization Request

Coverage Authorization Appeals

Learn More

Benefits investigation

Combined Prescriber Service Form and Patient Consent Form

Patient Consent Form - English

Patient Consent Form - Spanish

Prescriber Service Form - Online Portal

Learn More

Reimbursement help (FRM)

NOT PROVIDED BY BRANDReimbursement help (FRM) resources

Learn More

financial assistance

Tecentriq Financial assistance options

Co-pay savings program

commercial only

Combined Prescriber Service Form and Patient Consent Form

Patient Consent Form - English

Patient Consent Form - Spanish

Prescriber Service Form - Online Portal

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Combined Prescriber Service Form and Patient Consent Form

Patient Consent Form - English

Patient Consent Form - Spanish

Prescriber Service Form - Online Portal

Genentech Patient Foundation Application Form - Prescriber Form

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Tecentriq Patient education